Vigonvita Life Sciences Co., Ltd. (2630.HK) Stock Competitors & Peer Comparison

2630.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2630.HK stands at 4.4B. In comparison, 1093.HK has a market cap of 95.9B. Regarding current trading prices, 2630.HK is priced at HK$75.05, while 1093.HK trades at HK$8.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2630.HK currently has a P/E ratio of -24.67, whereas 1093.HK's P/E ratio is 22.56. In terms of profitability, 2630.HK's ROE is N/A, compared to 1093.HK's ROE of +0.11%. Regarding short-term risk, 2630.HK is more volatile compared to 1093.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2630.HK.Check 1093.HK's competition here

2630.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2630.HK stands at 4.4B. In comparison, 2186.HK has a market cap of 8.7B. Regarding current trading prices, 2630.HK is priced at HK$75.05, while 2186.HK trades at HK$2.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2630.HK currently has a P/E ratio of -24.67, whereas 2186.HK's P/E ratio is 12.10. In terms of profitability, 2630.HK's ROE is N/A, compared to 2186.HK's ROE of +0.04%. Regarding short-term risk, 2630.HK is more volatile compared to 2186.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2630.HK.Check 2186.HK's competition here

2630.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2630.HK stands at 4.4B. In comparison, 1666.HK has a market cap of 4.5B. Regarding current trading prices, 2630.HK is priced at HK$75.05, while 1666.HK trades at HK$3.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2630.HK currently has a P/E ratio of -24.67, whereas 1666.HK's P/E ratio is 9.60. In terms of profitability, 2630.HK's ROE is N/A, compared to 1666.HK's ROE of +0.05%. Regarding short-term risk, 2630.HK is more volatile compared to 1666.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2630.HK.Check 1666.HK's competition here

2630.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2630.HK stands at 4.4B. In comparison, 7630.HK has a market cap of 3.5B. Regarding current trading prices, 2630.HK is priced at HK$75.05, while 7630.HK trades at HK$12.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2630.HK currently has a P/E ratio of -24.67, whereas 7630.HK's P/E ratio is -10.27. In terms of profitability, 2630.HK's ROE is N/A, compared to 7630.HK's ROE of +0.33%. Regarding short-term risk, 2630.HK is more volatile compared to 7630.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2630.HK.Check 7630.HK's competition here

2630.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2630.HK stands at 4.4B. In comparison, 2410.HK has a market cap of 3.2B. Regarding current trading prices, 2630.HK is priced at HK$75.05, while 2410.HK trades at HK$8.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2630.HK currently has a P/E ratio of -24.67, whereas 2410.HK's P/E ratio is -25.61. In terms of profitability, 2630.HK's ROE is N/A, compared to 2410.HK's ROE of -0.77%. Regarding short-term risk, 2630.HK is less volatile compared to 2410.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2630.HK.Check 2410.HK's competition here

2630.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2630.HK stands at 4.4B. In comparison, 6086.HK has a market cap of 1.1B. Regarding current trading prices, 2630.HK is priced at HK$75.05, while 6086.HK trades at HK$0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2630.HK currently has a P/E ratio of -24.67, whereas 6086.HK's P/E ratio is -1482.14. In terms of profitability, 2630.HK's ROE is N/A, compared to 6086.HK's ROE of +0.08%. Regarding short-term risk, 2630.HK is more volatile compared to 6086.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2630.HK.Check 6086.HK's competition here

2630.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2630.HK stands at 4.4B. In comparison, 2563.HK has a market cap of 769.4M. Regarding current trading prices, 2630.HK is priced at HK$75.05, while 2563.HK trades at HK$3.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2630.HK currently has a P/E ratio of -24.67, whereas 2563.HK's P/E ratio is -8.66. In terms of profitability, 2630.HK's ROE is N/A, compared to 2563.HK's ROE of -0.19%. Regarding short-term risk, 2630.HK is more volatile compared to 2563.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2630.HK.Check 2563.HK's competition here

2630.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2630.HK stands at 4.4B. In comparison, 1643.HK has a market cap of 590.4M. Regarding current trading prices, 2630.HK is priced at HK$75.05, while 1643.HK trades at HK$0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2630.HK currently has a P/E ratio of -24.67, whereas 1643.HK's P/E ratio is -41.00. In terms of profitability, 2630.HK's ROE is N/A, compared to 1643.HK's ROE of -0.03%. Regarding short-term risk, 2630.HK is more volatile compared to 1643.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2630.HK.Check 1643.HK's competition here